Vigene Biosciences
Rockville, MD
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
72.5
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (13)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Vigene Biosciences
- Signal Score
- 72.5/100 (as of 2026-04-02)
- Quality Compliance
- Assessment pending
- Headquarters
- Rockville, MD
- Modalities
- AAV, Lentiviral, Adenoviral
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Adenoviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
74.0
Strong industry presence in SEC filings (219 mentions)
Major facility investment disclosed in SEC filings
Multiple manufacturing risk factors in SEC filings
Source: SEC EDGAR, press monitoring
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Strong industry presence in SEC filings (219 mentions)
Major facility investment disclosed in SEC filings
Multiple manufacturing risk factors in SEC filings
Capacity
71.0
10 facility investment mentions in SEC filings
Sites: Rockville, MD
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
10 facility investment mentions in SEC filings
Financial Intelligence
"Planned Divestiture of CDMO and Cell Solutions Businesses
On February 25, 2026, Charles River Laboratories International, Inc."
"(the “Company”) announced that it has signed a definitive agreement to divest its contract development and manufacturing products and services (“CDMO”) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments."
"The CDMO business provides services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies including viral vectors and plasmid DNA; and the Cell Solutions business provides human-derived cellular materials used in the development and production of cell therapies."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the nine months ended September 27, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the six months ended June 28, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the three months ended March 29, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
Source: SEC EDGAR · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.2
AAV, Lentiviral, Plasmid DNA, Adenoviral
Exothera
Jumet, BE
Signal Score: 78.1
AAV, Adenoviral, Lentiviral
Advent Bioservices
London, UK
Signal Score: 78.1
AAV, Lentiviral, Adenoviral
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 81.5
AAV, Lentiviral, Biologics